In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $8.28 in the last session, down -0.36% from day before closing price of $8.31. In other words, the price has decreased by -$0.36 from its previous closing price. On the day, 0.83 million shares were traded. DAWN stock price reached its highest trading level at $8.39 during the session, while it also had its lowest trading level at $7.99.
Ratios:
We take a closer look at DAWN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.61 and its Current Ratio is at 7.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when York Charles N II sold 4,370 shares for $11.96 per share. The transaction valued at 52,278 led to the insider holds 252,638 shares of the business.
Dubow Adam sold 4,646 shares of DAWN for $55,580 on Feb 18 ’25. The GENERAL COUNSEL now owns 39,602 shares after completing the transaction at $11.96 per share. On Feb 18 ’25, another insider, Bender Jeremy, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 12,048 shares for $11.96 each. As a result, the insider received 144,130 and left with 128,015 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 839219392 and an Enterprise Value of 310097408. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.40 while its Price-to-Book (P/B) ratio in mrq is 1.67. Its current Enterprise Value per Revenue stands at 2.364 whereas that against EBITDA is -1.472.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.33, which has changed by -0.47561747 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $7.88. The 50-Day Moving Average of the stock is -23.35%, while the 200-Day Moving Average is calculated to be -36.96%.
Shares Statistics:
According to the various share statistics, DAWN traded on average about 1.18M shares per day over the past 3-months and 1102420 shares per day over the past 10 days. A total of 101.12M shares are outstanding, with a floating share count of 74.28M. Insiders hold about 26.71% of the company’s shares, while institutions hold 83.56% stake in the company. Shares short for DAWN as of 1741910400 were 17024478 with a Short Ratio of 15.35, compared to 1739491200 on 17497763. Therefore, it implies a Short% of Shares Outstanding of 17024478 and a Short% of Float of 20.27.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Day One Biopharmaceuticals Inc (DAWN) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.26 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$0.75 and -$2.75 for the fiscal current year, implying an average EPS of -$1.4. EPS for the following year is -$0.71, with 8.0 analysts recommending between $0.34 and -$2.66.
Revenue Estimates
For the next quarter, 9 analysts are estimating revenue of $38.09M. There is a high estimate of $41.57M for the next quarter, whereas the lowest estimate is $31.5M.
A total of 10 analysts have provided revenue estimates for DAWN’s current fiscal year. The highest revenue estimate was $187.17M, while the lowest revenue estimate was $135.5M, resulting in an average revenue estimate of $163.95M. In the same quarter a year ago, actual revenue was $131.16MBased on 10 analysts’ estimates, the company’s revenue will be $272.23M in the next fiscal year. The high estimate is $325M and the low estimate is $203.3M.
